These SLG variants include oncogenic germline variants validated by outside groups, such as the TP53 R248Q alteration confirmed as germline by tumor-normal analysis of a pediatric glioma case.10 SLG variants in cancer genes also associated with earlier age of diagnosis in patients with low-grade glioma (Fig. 4a), suggesting that TOBI’s SLG variants are enriched for cancer-associated variants. This evidence concerns the gene TP53 and central nervous system cancer.